Otsuka Pharmaceutical Co., Ltd.
GPTKB entity
Properties (116)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:Company
|
| gptkbp:acquisition |
gptkb:Avanir_Pharmaceuticals
gptkb:TetraLogic_Pharmaceuticals Astex_Pharmaceuticals_(2013) Avanir_Pharmaceuticals_(2014) Mr._Shigeo_Matsumoto |
| gptkbp:advertising |
gptkb:Ms._Yuki_Matsumoto
gptkb:Dr._Hiroshi_Yamamoto gptkb:Mr._Kenji_Yamamoto gptkb:Mr._Hiroshi_Nakagawa gptkb:Mr._Hiroshi_Tanaka gptkb:Ms._Akiko_Suzuki gptkb:Mr._Hiroshi_Yamamoto gptkb:Ms._Yuki_Tanaka Mr. Hiroshi Sato Mr. Takashi Sato Mr. Masato Fujimoto Mr. Masato Nishida Ms._Akiko_Yamamoto Dr._Yuki_Takahashi Mr._Kazuhiro_Ito Mr._Kazuhiro_Saito Mr._Ryoichi_Matsuda Mr._Ryuji_Tanaka Mr._Shunichi_Nakagawa Mr._Taro_Nishimura Mr._Tetsuya_Sakamoto Ms._Naomi_Takahashi Ms._Rika_Sakamoto Ms._Sayaka_Yoshida Ms._Yoko_Sato Ms._Yoko_Takeda Ms._Yumi_Takeda |
| gptkbp:CEO |
gptkb:Taro_Iwamoto
Akihiko_Otsuka_(former) Mr._Yoshio_Sakamoto |
| gptkbp:clinicalTrials |
Mr._Kenta_Matsumoto
Otsuka_Clinical_Research_Institute |
| gptkbp:community |
gptkb:Ms._Aiko_Tanaka
Ms._Yoko_Taniguchi |
| gptkbp:customerService |
Ms._Aiko_Fujimoto
|
| gptkbp:employees |
approximately 47,000
approximately 47,000 (2020) |
| gptkbp:evaluates |
Ms._Miki_Sato
|
| gptkbp:founded |
1964
|
| gptkbp:founder |
gptkb:Akihiko_Otsuka
|
| gptkbp:global_presence |
Operations in over 30 countries
|
| gptkbp:globalPresence |
Mr._Hiroshi_Kudo
Ms._Keiko_Taniguchi |
| gptkbp:governance |
Ms._Aki_Yoshida
|
| gptkbp:headCoach |
Mr._Ryoichi_Matsumoto
Mr._Shohei_Nakamura Ms._Yui_Sakamoto |
| gptkbp:headquarters |
gptkb:Tokyo,_Japan
|
| gptkbp:healthcare |
gptkb:Mr._Shunji_Takeda
Ms._Akira_Yoshikawa |
| https://www.w3.org/2000/01/rdf-schema#label |
Otsuka Pharmaceutical Co., Ltd.
|
| gptkbp:industry |
Pharmaceuticals
|
| gptkbp:internationalCooperation |
Mr._Koji_Yamashita
|
| gptkbp:market |
gptkb:Mr._Tetsuya_Yamashita
|
| gptkbp:notableFeature |
gptkb:Samsca
gptkb:Rexulti Abilify Seroquel |
| gptkbp:operations |
Mr._Yoshihiro_Matsuda
Ms._Natsuki_Tanaka |
| gptkbp:partnerships |
gptkb:Mitsubishi_Tanabe_Pharma_Corporation
gptkb:AstraZeneca gptkb:Bristol-Myers_Squibb gptkb:Eisai_Co.,_Ltd. gptkb:Helsinn_Healthcare gptkb:Mitsubishi_Tanabe_Pharma Mr._Yuji_Takahashi |
| gptkbp:philanthropy |
gptkb:Otsuka_Medical_Research_Institute
gptkb:Otsuka_Foundation Otsuka_Pharmaceutical_Co.,_Ltd._Scholarship_Program |
| gptkbp:products |
Medical devices
Prescription drugs Nutraceuticals |
| gptkbp:regulatoryCompliance |
gptkb:Mr._Yoshio_Takeda
gptkb:Ms._Rika_Watanabe gptkb:Mr._Kenjiro_Matsumoto Mr._Takashi_Suzuki Ms._Akiko_Matsumoto Ms._Akiko_Nishida Ms._Haruko_Yamashita |
| gptkbp:research |
gptkb:Dr._Masahiro_Kuroda
Ms._Haruto_Watanabe Otsuka_Research_Institute |
| gptkbp:research_focus |
Oncology
Cardiovascular diseases Infectious diseases Central nervous system disorders |
| gptkbp:revenue |
¥1.5 trillion (2020)
$11.5 billion (2020) |
| gptkbp:riskManagement |
Mr._Takuya_Yamamoto
|
| gptkbp:scientificName |
Mr._Masaki_Tanaka
|
| gptkbp:social_responsibility |
Mr._Riku_Tanaka
|
| gptkbp:specialization |
Oncology
Cardiovascular diseases Infectious diseases Central nervous system disorders |
| gptkbp:subsidiary |
gptkb:Otsuka_America_Pharmaceutical,_Inc.
Otsuka_Pharmaceutical_Europe_Ltd. Otsuka_Pharmaceutical_Co.,_Ltd._(Europe) |
| gptkbp:supplyChain |
gptkb:Mr._Taro_Yamada
Mr._Junichi_Watanabe Mr._Masahiro_Sato |
| gptkbp:sustainability |
Mr. Junpei Kato
|
| gptkbp:tactics |
gptkb:Mr._Kenjiro_Takahashi
Mr._Kazuya_Saito Mr._Tetsuya_Kobayashi Ms._Haruka_Saito Ms._Haruka_Tanaka Ms._Rina_Kobayashi |
| gptkbp:website |
www.otsuka.com
|